Home > Comparison > Healthcare > ISRG vs HOLX
The strategic rivalry between Intuitive Surgical, Inc. and Hologic, Inc. shapes the healthcare instruments sector. Intuitive Surgical leads with a capital-intensive, innovation-driven surgical robotics model. Hologic operates as a diversified medical diagnostics and imaging provider focused on women’s health. This analysis pits cutting-edge technology against broad diagnostic reach, assessing which trajectory offers superior risk-adjusted returns for a diversified portfolio in today’s evolving healthcare landscape.
Table of contents
Companies Overview
Intuitive Surgical and Hologic both command influential roles in the medical instruments and supplies sector.
Intuitive Surgical, Inc.: Pioneer in Minimally Invasive Surgical Systems
Intuitive Surgical dominates the minimally invasive surgery equipment market. It generates revenue primarily through sales and services of the da Vinci Surgical System, complemented by diagnostic tools like the Ion endoluminal system. In 2026, it sharpens its strategic focus on expanding digital capabilities to integrate performance insights and streamline hospital operations.
Hologic, Inc.: Specialist in Women’s Health Diagnostics and Surgical Products
Hologic stands out in women’s health diagnostics and surgical solutions. Its revenue engine spans molecular diagnostics, breast imaging, and surgical systems targeting early detection and treatment. The company’s 2026 strategy emphasizes innovation across diagnostics and breast health while broadening its global sales footprint.
Strategic Collision: Similarities & Divergences
Both operate in healthcare instruments but diverge sharply in focus—Intuitive Surgical leans on advanced robotic surgery, while Hologic centers on diagnostics and women’s health solutions. Their competitive battleground lies in advancing minimally invasive procedures versus diagnostic precision. This contrast shapes distinct investment profiles: Intuitive Surgical offers growth through robotics innovation; Hologic presents steady demand via diversified diagnostic platforms.
Income Statement Comparison
This data dissects the core profitability and scalability of both corporate engines to reveal who dominates the bottom line:
| Metric | Intuitive Surgical, Inc. (ISRG) | Hologic, Inc. (HOLX) |
|---|---|---|
| Revenue | 10.1B | 4.1B |
| Cost of Revenue | 3.41B | 1.60B |
| Operating Expenses | 3.71B | 1.79B |
| Gross Profit | 6.66B | 2.50B |
| EBITDA | 3.31B | 1.02B |
| EBIT | 3.31B | 724M |
| Interest Expense | 0 | 43M |
| Net Income | 2.86B | 566M |
| EPS | 8.00 | 2.50 |
| Fiscal Year | 2025 | 2025 |
Income Statement Analysis: The Bottom-Line Duel
This income statement comparison reveals which company operates more efficiently and delivers stronger profitability in a competitive medical technology landscape.
Intuitive Surgical, Inc. Analysis
Intuitive Surgical shows robust revenue growth from $5.7B in 2021 to $10.1B in 2025, with net income surging from $1.7B to $2.9B. Its gross margin holds strong at 66.1%, while net margin remains favorable at 28.4%. The latest year highlights accelerating EBIT growth of 41%, indicating excellent operating leverage and momentum.
Hologic, Inc. Analysis
Hologic’s revenue declined from $5.6B in 2021 to $4.1B in 2025, dragging net income down from $1.9B to $566M. Despite a decent gross margin near 61%, net margin halved to 13.8%. The latest year shows a sharp EBIT drop of 27%, reflecting operational challenges and weakening profitability momentum.
Verdict: Growth Dynamo vs. Declining Scale
Intuitive Surgical outperforms Hologic decisively in both top-line expansion and margin strength. Its superior EBIT margin of nearly 33% and rapid EPS growth contrast sharply with Hologic’s shrinking revenues and profits. Intuitive’s profile appeals more to investors seeking sustainable, efficient growth in medical tech.
Financial Ratios Comparison
These vital ratios serve as a diagnostic tool to reveal underlying fiscal health, valuation premiums, and capital efficiency for the following companies:
| Ratios | Intuitive Surgical, Inc. (ISRG) | Hologic, Inc. (HOLX) |
|---|---|---|
| ROE | 14.13% (2024) | 15.39% (2024) |
| ROIC | 11.99% (2024) | 9.84% (2024) |
| P/E | 79.82 (2024) | 24.32 (2025) |
| P/B | 11.28 (2024) | 3.02 (2025) |
| Current Ratio | 4.07 (2024) | 3.75 (2025) |
| Quick Ratio | 3.22 (2024) | 3.06 (2025) |
| D/E | 0.01 (2024) | 0.52 (2025) |
| Debt-to-Assets | 0.78% (2024) | 29.14% (2025) |
| Interest Coverage | N/A | 16.73 (2025) |
| Asset Turnover | 0.44 (2024) | 0.45 (2025) |
| Fixed Asset Turnover | 1.75 (2024) | 6.27 (2025) |
| Payout ratio | 0% | 0% |
| Dividend yield | 0% | 0% |
| Fiscal Year | 2024 | 2025 |
Efficiency & Valuation Duel: The Vital Signs
Financial ratios act as the company’s DNA, revealing hidden risks and operational excellence beneath headline numbers.
Intuitive Surgical, Inc.
Intuitive Surgical posts a strong net margin of 28.38%, signaling efficient core profitability despite zero reported ROE and ROIC for 2025. The stock trades at a stretched P/E of 70.78, indicating high valuation risk. With no dividends, the company reinvests heavily in R&D (13.7% of revenue), driving future growth potential.
Hologic, Inc.
Hologic shows moderate profitability with a net margin of 13.8% and a neutral ROE of 11.21%. Its valuation appears more reasonable at a P/E of 26.99, though the P/B ratio of 3.02 suggests some premium. The firm maintains a solid balance sheet and reinvests through moderate R&D (6.5% of revenue), supporting steady operational efficiency.
Premium Valuation vs. Operational Safety
Intuitive Surgical’s high margin and aggressive R&D come at the cost of an elevated P/E and uncertain returns. Hologic balances modest profitability with a more conservative valuation and better liquidity ratios. Investors seeking growth might prefer Intuitive’s profile, while those prioritizing stability and valuation favor Hologic’s approach.
Which one offers the Superior Shareholder Reward?
Intuitive Surgical (ISRG) pays no dividends but retains substantial free cash flow for growth, with a high P/E around 79 and no buybacks reported, suggesting reinvestment over payouts. Hologic (HOLX) also pays no dividends but shows strong free cash flow (4B+), moderate leverage, and a lower P/E near 27. Both lack buyback intensity, but HOLX’s lower valuation and robust free cash flow coverage signal a more sustainable distribution strategy. I conclude HOLX offers the superior total shareholder reward in 2026, balancing growth reinvestment and value creation better than ISRG.
Comparative Score Analysis: The Strategic Profile
The radar chart reveals the fundamental DNA and trade-offs of Intuitive Surgical, Inc. and Hologic, Inc., highlighting their financial strengths and vulnerabilities:
Hologic dominates in discounted cash flow, ROE, and ROA, reflecting efficient asset use and profitability. Intuitive Surgical trails with uniformly low scores, signaling financial distress and valuation concerns. Hologic presents a more balanced profile, while Intuitive relies on a moderate DCF score amid broad weaknesses.
Bankruptcy Risk: Solvency Showdown
Intuitive Surgical’s Altman Z-Score far exceeds Hologic’s, placing both safely above bankruptcy risk. However, Intuitive’s extreme score signals exceptional solvency, while Hologic remains comfortably stable in this cycle:
Financial Health: Quality of Operations
Hologic scores an 8 on the Piotroski scale, indicating very strong financial health and operational strength. Intuitive Surgical’s score of 5 flags average performance with potential red flags in internal metrics compared to Hologic’s robust profile:
How are the two companies positioned?
This section dissects the operational DNA of ISRG and HOLX by comparing their revenue distribution and internal dynamics. The goal is to confront their economic moats to identify which business model offers the most resilient competitive advantage today.
Revenue Segmentation: The Strategic Mix
This visual comparison dissects how Intuitive Surgical and Hologic diversify their income streams and where their primary sector bets lie:
Intuitive Surgical anchors revenue in Instruments and Accessories with $5.08B in 2024, supported by Systems at $1.97B and Services $1.31B, showing moderate diversification. Hologic pivots on Diagnostics with $1.78B and Breast Health at $1.52B, but also spreads risk across Gyn Surgical and Skeletal Health. Intuitive’s focus suggests ecosystem lock-in via proprietary instruments; Hologic balances infrastructure dominance with product breadth, lowering concentration risk.
Strengths and Weaknesses Comparison
This table compares the Strengths and Weaknesses of Intuitive Surgical, Inc. and Hologic, Inc.:
Intuitive Surgical, Inc. Strengths
- High net margin at 28.38%
- Favorable debt-to-assets and interest coverage
- Strong revenue growth in Instruments and Accessories
- Diverse product segments including Systems and Services
Hologic, Inc. Strengths
- Favorable net margin at 13.8%
- Positive ROIC above WACC at 7.35%
- Strong liquidity with quick ratio at 3.06
- Robust fixed asset turnover of 6.27
- Significant revenue diversification across Diagnostics and Breast Health
Intuitive Surgical, Inc. Weaknesses
- Unfavorable ROE and ROIC at 0%
- Unavailable WACC data
- Poor liquidity ratios (current and quick ratio at 0)
- High P/E at 70.78 suggests overvaluation
- Low asset turnover
- No dividend yield
Hologic, Inc. Weaknesses
- Moderate ROE and ROIC with neutral status
- Unfavorable P/E and P/B ratios indicating valuation concerns
- Current ratio above 3.7 flagged as unfavorable
- Asset turnover at 0.45 is low
- No dividend yield
Both companies show strengths in profitability but differ in valuation and liquidity profiles. Intuitive Surgical’s high margin contrasts with weak capital efficiency and liquidity. Hologic demonstrates better operational efficiency and liquidity but faces valuation and turnover challenges. These factors shape each firm’s strategic financial positioning.
The Moat Duel: Analyzing Competitive Defensibility
A structural moat protects long-term profits from relentless competition erosion. Without it, market share and margins erode rapidly:
Intuitive Surgical, Inc. (ISRG): Innovation-Driven Switching Costs
Intuitive Surgical’s moat stems from high switching costs driven by its da Vinci system’s entrenched surgical ecosystem. Its stable 66% gross margin and 33% EBIT margin reflect this premium positioning. Yet, declining ROIC signals potential margin pressure as new products like Ion lung biopsy system may expand or strain this advantage in 2026.
Hologic, Inc. (HOLX): Diversified Diagnostic and Imaging Intangible Assets
Hologic relies on a broad portfolio of diagnostic tests and imaging tech, creating intangible asset moats unlike ISRG’s device lock-in. However, its lower 61% gross margin and shrinking EBIT margin alongside declining ROIC reveal eroding profitability. Growth constraints and regional revenue drops challenge HOLX’s ability to deepen its moat in 2026.
Innovation Lock-in vs. Portfolio Breadth: The Moat Verdict
Intuitive Surgical’s switching cost moat is deeper and better entrenched than Hologic’s intangible asset base. Despite some ROIC decline, ISRG’s focused innovation and margin strength equip it better to defend market share against competitive threats in 2026.
Which stock offers better returns?
The past year shows Intuitive Surgical’s stock rising sharply by 28.7%, then slowing down, while Hologic’s shares declined by 2.75% amid accelerating bearish momentum.
Trend Comparison
Intuitive Surgical’s stock gained 28.7% over the past year, indicating a bullish trend with decelerating momentum and high volatility, ranging between 366.34 and 595.55.
Hologic’s shares fell 2.75% in the same period, reflecting a bearish trend with accelerating downside and low volatility, reaching a high of 83.64 and a low near 54.16.
Intuitive Surgical outperformed Hologic with a strong positive return, despite recent deceleration, while Hologic posted a moderate bearish trend overall.
Target Prices
Analysts show a confident upward target consensus for Intuitive Surgical and Hologic.
| Company | Target Low | Target High | Consensus |
|---|---|---|---|
| Intuitive Surgical, Inc. | 550 | 750 | 641.25 |
| Hologic, Inc. | 76 | 79 | 77.8 |
The target consensus for Intuitive Surgical at 641.25 implies a 27% upside from the current 504.22 stock price, signaling strong growth expectations. Hologic’s consensus at 77.8 suggests a modest 4% upside, reflecting more cautious optimism.
Don’t Let Luck Decide Your Entry Point
Optimize your entry points with our advanced ProRealTime indicators. You’ll get efficient buy signals with precise price targets for maximum performance. Start outperforming now!
How do institutions grade them?
The following tables summarize recent institutional grades for Intuitive Surgical, Inc. and Hologic, Inc.:
Intuitive Surgical, Inc. Grades
Here are the latest grades issued by recognized financial institutions for Intuitive Surgical, Inc.:
| Grading Company | Action | New Grade | Date |
|---|---|---|---|
| Freedom Capital Markets | Upgrade | Buy | 2026-01-27 |
| Barclays | Maintain | Overweight | 2026-01-26 |
| Bernstein | Maintain | Outperform | 2026-01-23 |
| Citigroup | Maintain | Neutral | 2026-01-23 |
| Evercore ISI Group | Maintain | In Line | 2026-01-23 |
| BTIG | Maintain | Buy | 2026-01-23 |
| Piper Sandler | Maintain | Overweight | 2026-01-23 |
| Bernstein | Maintain | Outperform | 2026-01-09 |
| Barclays | Maintain | Overweight | 2026-01-07 |
| BTIG | Maintain | Buy | 2026-01-07 |
Hologic, Inc. Grades
Below are the recent grades from reputable firms for Hologic, Inc.:
| Grading Company | Action | New Grade | Date |
|---|---|---|---|
| Argus Research | Downgrade | Hold | 2026-01-12 |
| Evercore ISI Group | Downgrade | In Line | 2026-01-05 |
| Morgan Stanley | Maintain | Equal Weight | 2025-11-11 |
| Mizuho | Downgrade | Neutral | 2025-10-23 |
| JP Morgan | Downgrade | Neutral | 2025-10-22 |
| Stephens & Co. | Downgrade | Equal Weight | 2025-10-22 |
| Raymond James | Downgrade | Market Perform | 2025-10-22 |
| Leerink Partners | Maintain | Market Perform | 2025-10-21 |
| Needham | Maintain | Hold | 2025-10-21 |
| BTIG | Maintain | Neutral | 2025-10-21 |
Which company has the best grades?
Intuitive Surgical, Inc. consistently holds higher grades such as Buy, Outperform, and Overweight. Hologic, Inc. shows a trend of downgrades toward Hold and Neutral. Investors may interpret Intuitive’s stronger grades as greater confidence from analysts.
Risks specific to each company
The following categories identify critical pressure points and systemic threats facing Intuitive Surgical, Inc. and Hologic, Inc. in the 2026 market environment:
1. Market & Competition
Intuitive Surgical, Inc.
- Dominates minimally invasive surgical systems but faces high innovation pressure and premium valuation risks.
Hologic, Inc.
- Competes across diagnostics and imaging with broader product lines but struggles with lower margins and fragmented markets.
2. Capital Structure & Debt
Intuitive Surgical, Inc.
- Virtually no debt, strong interest coverage, but liquidity ratios are weak, risking short-term flexibility.
Hologic, Inc.
- Moderate debt with solid interest coverage and healthier liquidity, balancing risk with operational needs.
3. Stock Volatility
Intuitive Surgical, Inc.
- High beta (1.67) implies significant stock volatility and market sensitivity.
Hologic, Inc.
- Lower beta (0.70) suggests relative stability and less susceptibility to market swings.
4. Regulatory & Legal
Intuitive Surgical, Inc.
- Operates under strict FDA scrutiny on innovative medical devices, increasing compliance costs.
Hologic, Inc.
- Faces regulatory risks across diagnostics and imaging with evolving healthcare policies in multiple regions.
5. Supply Chain & Operations
Intuitive Surgical, Inc.
- Complexity in manufacturing advanced surgical robots may cause supply bottlenecks.
Hologic, Inc.
- Diverse product portfolio demands complex supply chains but benefits from scale and distribution networks.
6. ESG & Climate Transition
Intuitive Surgical, Inc.
- ESG disclosures limited; potential risks as healthcare pivots to sustainability and carbon footprint reduction.
Hologic, Inc.
- More advanced ESG initiatives and reporting, better positioned for climate transition pressures.
7. Geopolitical Exposure
Intuitive Surgical, Inc.
- Global sales expose it to trade tensions and regulatory divergences, especially US-China relations.
Hologic, Inc.
- Also exposed internationally but with a more diversified geographic revenue base, mitigating some geopolitical risks.
Which company shows a better risk-adjusted profile?
Intuitive Surgical’s largest risk lies in high market volatility and stretched valuation metrics. Hologic faces significant operational complexity and moderate debt but benefits from broader diversification and stronger financial ratios. Hologic’s higher Piotroski score (8 vs. 5) and safer Altman Z-score highlight superior financial health. Recent data reveal Intuitive’s unfavorable liquidity and valuation metrics as red flags, while Hologic’s balanced capital structure and stable beta provide a better risk-adjusted profile for cautious investors.
Final Verdict: Which stock to choose?
Intuitive Surgical, Inc. (ISRG) showcases a superpower in its remarkable ability to generate strong free cash flow and maintain robust gross and EBIT margins. This cash machine excels in innovation with aggressive R&D but shows a point of vigilance in its sky-high valuation and declining ROIC trend. It suits aggressive growth portfolios willing to pay for future potential.
Hologic, Inc. (HOLX) builds its strategic moat on steady recurring revenues and a safer balance sheet, reflected in consistent free cash flow yields and a very strong Piotroski score. Its moderate valuation and tangible asset base provide better stability compared to ISRG. HOLX fits well in GARP portfolios that seek a balance between growth and value.
If you prioritize aggressive growth with exposure to cutting-edge medical innovation, ISRG is the compelling choice due to its cash-generating prowess and top-tier margins despite valuation risks. However, if you seek a more stable investment with a proven financial foundation and reasonable valuation, HOLX offers better stability and a stronger financial health profile. Both carry distinct risks, so alignment with your risk tolerance and investment horizon is key.
Disclaimer: Investment carries a risk of loss of initial capital. The past performance is not a reliable indicator of future results. Be sure to understand risks before making an investment decision.
Go Further
I encourage you to read the complete analyses of Intuitive Surgical, Inc. and Hologic, Inc. to enhance your investment decisions:
